Search
Centessa Pharmaceuticals PLC
CNTAAdd to Watchlist
39.590USD
-0.020-0.05%
Market hours （ET）Quotes delayed by 15 min
5.91BMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-0.05%
5 Days
-0.20%
1 Month
+0.28%
6 Months
+48.28%
Year to Date
+58.30%
1 Year
+201.06%
TradingKey Stock Score of Centessa Pharmaceuticals PLC
Currency: USD Updated: 2026-05-12Key Insights
Centessa Pharmaceuticals PLC's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 47 out of 383 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 44.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Centessa Pharmaceuticals PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Centessa Pharmaceuticals PLC Highlights
StrengthsRisks
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 118.88% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 15.00M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 15.00M.
Undervalued
The company’s latest PE is -22.31, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 150.25M shares, increasing 7.40% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 7.03K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.75.
Analyst Rating
Based on
13
analysts
Hold
Current Rating
44.000
Target Price
+11.14%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Centessa Pharmaceuticals PLC Info
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Ticker SymbolCNTA
CompanyCentessa Pharmaceuticals PLC
CEOSaha (Saurabh)
Websitehttps://www.centessa.com/
Related Instruments
+0.74%
+0.63%
+1.86%
-0.51%
+1.01%
+0.59%
-0.83%
-1.36%
+0.13%
+0.14%
-0.32%
+0.34%
-0.07%
+0.34%
+1.11%
-0.39%
0.00%
+0.55%
-1.51%
+0.02%Popular Instruments
100.562
+1.263 (+1.27%)
295.315
+0.515 (+0.17%)
223.420
+2.640 (+1.20%)
4681.630
-47.490 (-1.00%)
477.600
-11.140 (-2.28%)
1418.320
-33.700 (-2.32%)
788.135
+21.555 (+2.81%)
391.860
+4.510 (+1.16%)
79750.000
-916.870 (-1.14%)
437.110
+3.660 (+0.84%)
